We have a new spirit of Glasnost at DMX and I like it. So does the market.
We've seen a lot of complaints in the past that RK runs a one-woman show. Here's a little proof that that's not the case. The plant is Ruth Huttman's baby. I've seen many companies require a re-inspection. Dimethaid did it first time. They had no manufacturing experience as a company and were able to buy a plant, staff it, establish procedures, successfully ramp up production, and now obtain approval from the toughest regulatory body in the world. All with hardly a hiccup that we know of.
Laurel writes a great report. Thanks for getting permission to post it Mark. The report talked about a placebo effect for topical NSAIDs. I've thought about this as well. If there is such an effect, there's no reason to think it won't occur in 'real life' as well, which is good for us. I think however that the placebo effect may be smaller than expected because there is no rubbing of Pennsaid involved in applying it. I think Pennsaid has better results than the orals simply because more NSAID is delivered to where the pain is.
The 8 billion dollar number I see batted around recently is a little misleading. There are a lot of conditions (eg. Headaches) that oral NSAIDS are used for that Pennsaid can never be. Someone also mentioned veterinary usage. I think this requires separate approval that is unlikely to be undertaken. We'd be much better off doing studies on children, pregnant women, and some of the other groups that are currently contra indicated due to lack of data.
I'm starting to get excited again. We could have FDA approval, J&J deal signed, and WF10 results all in the next few months. Also, don't forget about the head to head studies against Diclofenac and Celebrex. Those studies won't take long and even the mass media would understand the significance.
How can Bay Street ignore this company any longer? I think coverage is imminent. But hell, I've thought that for 3 years now.
Dave |
